tranylcypromine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2715 155-09-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tranylcypromine
  • (RS)-trans-2-Phenylcyclopropylamine
  • tranylcypromine sulfate
  • tranylcypromine hydrochloride
  • tranylcypromine HCl
  • parnate
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
  • Molecular weight: 133.19
  • Formula: C9H11N
  • CLOGP: 1.48
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -1.95
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 48 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.44 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Feb. 21, 1961 FDA COVIS PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertensive crisis 192.72 46.87 48 1308 15238 63472428
Potentiating drug interaction 167.16 46.87 34 1322 4322 63483344
Labelled drug-food interaction medication error 117.09 46.87 16 1340 168 63487498
Drug interaction 74.23 46.87 51 1305 229080 63258586
Serotonin syndrome 72.30 46.87 26 1330 28656 63459010
Diet noncompliance 68.01 46.87 11 1345 382 63487284
Congenital central nervous system anomaly 62.21 46.87 10 1346 334 63487332
Drug dose titration not performed 57.61 46.87 10 1346 535 63487131
Atrioventricular septal defect 55.80 46.87 9 1347 307 63487359
Craniosynostosis 53.29 46.87 8 1348 169 63487497
Food interaction 47.03 46.87 9 1347 829 63486837

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 44.76 41.51 13 295 17921 34938702

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertensive crisis 175.28 40.44 44 1143 20726 79722475
Serotonin syndrome 104.61 40.44 35 1152 44992 79698209
Potentiating drug interaction 101.38 40.44 24 1163 8795 79734406
Labelled drug-food interaction medication error 72.75 40.44 10 1177 162 79743039
Drug dose titration not performed 70.91 40.44 12 1175 798 79742403
Drug interaction 59.42 40.44 49 1138 415134 79328067
Contraindicated product administered 54.35 40.44 32 1155 157506 79585695
Neuroleptic malignant syndrome 46.84 40.44 17 1170 27542 79715659
Food interaction 43.92 40.44 9 1178 1693 79741508

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AF04 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Monoamine oxidase inhibitors, non-selective
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:38623 monoamine oxidase inhibitors
CHEBI has role CHEBI:50183 P450 inhibitors
CHEBI has role CHEBI:131509 LSD1 inhibitor
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175744 Monoamine Oxidase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Bipolar disorder contraindication 13746004 DOID:3312
Feeling agitated contraindication 24199005
Orthostatic hypotension contraindication 28651003
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Anxiety contraindication 48694002
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Schizophrenia contraindication 58214004 DOID:5419
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Syncope contraindication 271594007
Pheochromocytoma contraindication 302835009
Myelogram contraindication 367401004
Disorder of coronary artery contraindication 414024009
Severe Headache Disorder contraindication
Hypertensive Emergencies contraindication
Frequent Headache Disorder contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR IC50 7.48 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.23 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.29 PDSP
Cytochrome P450 2A6 Enzyme Ki 7.19 WOMBAT-PK
Amine oxidase [flavin-containing] A Enzyme IC50 6.62 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 5.30 CHEMBL
Cytochrome P450 2B6 Enzyme IC50 5.16 CHEMBL
Lysine-specific histone demethylase 1A Enzyme Ki 4.60 CHEMBL
Lysine-specific histone demethylase 1B Enzyme IC50 4.46 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.23 PDSP
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.11 CHEMBL
Cationic trypsin Enzyme Ki 4.88 CHEMBL
D(2) dopamine receptor GPCR Ki 4.23 CHEMBL
Amine oxidase [flavin-containing] B Enzyme IC50 7.11 CHEMBL
Amine oxidase [flavin-containing] A Enzyme IC50 6.54 CHEMBL
D(3) dopamine receptor GPCR Ki 4.89 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane other Ki 5.75 CHEMBL
Sigma intracellular receptor 2 Unclassified Ki 5.21 CHEMBL

External reference:

IDSource
4019953 VUID
N0000148038 NUI
D00826 KEGG_DRUG
13492-01-8 SECONDARY_CAS_RN
4018013 VANDF
4019953 VANDF
C0040778 UMLSCUI
CHEBI:9652 CHEBI
1LP PDB_CHEM_ID
CHEMBL3989843 ChEMBL_ID
CHEMBL1179 ChEMBL_ID
CHEMBL313833 ChEMBL_ID
19493 PUBCHEM_CID
DB00752 DRUGBANK_ID
CHEMBL3989698 ChEMBL_ID
D014191 MESH_DESCRIPTOR_UI
986 INN_ID
5281 IUPHAR_LIGAND_ID
1986-47-6 SECONDARY_CAS_RN
3E3V44J4Z9 UNII
10734 RXNORM
4529 MMSL
5608 MMSL
84239 MMSL
d00884 MMSL
001496 NDDF
004597 NDDF
372891006 SNOMEDCT_US
89092006 SNOMEDCT_US
89772006 SNOMEDCT_US
CHEMBL1255743 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tranylcypromine HUMAN PRESCRIPTION DRUG LABEL 1 0527-3010 TABLET 10 mg ORAL ANDA 30 sections
Tranylcypromine Sulfate Human Prescription Drug Label 1 0591-5590 TABLET, FILM COATED 10 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Tranylcypromine Sulfate Human Prescription Drug Label 1 0591-5590 TABLET, FILM COATED 10 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Tranylcypromine HUMAN PRESCRIPTION DRUG LABEL 1 10135-739 TABLET 10 mg ORAL ANDA 28 sections
Tranylcypromine HUMAN PRESCRIPTION DRUG LABEL 1 10135-739 TABLET 10 mg ORAL ANDA 28 sections
Tranylcypromine HUMAN PRESCRIPTION DRUG LABEL 1 43547-655 TABLET 10 mg ORAL ANDA 30 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 49884-032 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 49884-032 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
PARNATE Human Prescription Drug Label 1 59212-447 TABLET, FILM COATED 10 mg ORAL NDA 28 sections
PARNATE Human Prescription Drug Label 1 59212-447 TABLET, FILM COATED 10 mg ORAL NDA 28 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 60429-210 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 63629-2247 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 64380-176 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
TRANYLCYPROMINE SULFATE HUMAN PRESCRIPTION DRUG LABEL 1 64380-176 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tranylcypromine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 64980-183 TABLET 10 mg ORAL NDA 16 sections
Tranylcypromine Human Prescription Drug Label 1 70954-538 TABLET 10 mg ORAL ANDA 29 sections